{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:09:07Z","timestamp":1792807747016,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","thrombosisresearch.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.thromres.2018.01.006","type":"journal-article","created":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T11:38:28Z","timestamp":1524656308000},"page":"S119-S123","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S1","title":["Antidotes for the direct oral anticoagulants: What news?"],"prefix":"10.1016","volume":"164","author":[{"given":"S.","family":"Galliazzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Donadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Ageno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"38","key":"10.1016\/j.thromres.2018.01.006_bb0005","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur. Heart J."},{"issue":"2","key":"10.1016\/j.thromres.2018.01.006_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"issue":"12","key":"10.1016\/j.thromres.2018.01.006_bb0015","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2014-04-571232","article-title":"Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials","volume":"124","author":"van Es","year":"2014","journal-title":"Blood"},{"issue":"383","key":"10.1016\/j.thromres.2018.01.006_bb0020","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"15","author":"Ruff","year":"2014","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.thromres.2018.01.006_bb0025","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood-2014-07-590323","article-title":"The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis","volume":"124","author":"Chai-Adisaksopha","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.thromres.2018.01.006_bb0030","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/jth.13139","article-title":"Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J. Thromb. Haemost."},{"issue":"22","key":"10.1016\/j.thromres.2018.01.006_bb0035","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","author":"Larsen","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.thromres.2018.01.006_bb0040","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1160\/TH14-11-0954","article-title":"Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC registry","volume":"113","author":"Beyer-Westendorf","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2018.01.006_bb0045","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1016\/S2352-3026(15)00257-4","article-title":"Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study","volume":"3","author":"Ageno","year":"2016","journal-title":"Lancet Haematol."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.006_bb0050","first-page":"975","article-title":"Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis","volume":"116","author":"Lip","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2018.01.006_bb0055","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamainternmed.2014.5398","article-title":"Risk of bleeding with dabigatran in atrial fibrillation","volume":"175","author":"Hernandez","year":"2015","journal-title":"JAMA Intern. Med."},{"issue":"14","key":"10.1016\/j.thromres.2018.01.006_bb0060","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/eurheartj\/ehv466","article-title":"XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation","volume":"37","author":"Camm","year":"2016","journal-title":"Eur. Heart J."},{"issue":"21","key":"10.1016\/j.thromres.2018.01.006_bb0065","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.thromres.2018.01.006_bb0070","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1001\/jama.2016.16201","article-title":"Visits for outpatient adverse drug events, 2013\u20132014","volume":"316","author":"Shehab","year":"2016","journal-title":"JAMA"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2018.01.006_bb0075","doi-asserted-by":"crossref","first-page":"e152S","DOI":"10.1378\/chest.11-2295","article-title":"Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Holbrook","year":"2012","journal-title":"Chest"},{"issue":"27","key":"10.1016\/j.thromres.2018.01.006_bb0080","first-page":"2137","article-title":"Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary","volume":"38","author":"Heidbuchel","year":"2017","journal-title":"Eur. Heart J."},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2018.01.006_bb0085","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.thromres.2018.01.006_bb0090","first-page":"1003","article-title":"Managing reversal of direct oral anticoagulants in emergency situations. Anticoagulation education task force white paper","volume":"116","author":"Ageno","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.006_bb0095","doi-asserted-by":"crossref","first-page":"198","DOI":"10.5694\/mja12.10614","article-title":"Australasian Society of Thrombosis and Haemostasis (ASTH), an update of consensus guidelines for warfarin reversal","volume":"198","author":"Tran","year":"2013","journal-title":"Med. J. Aust."},{"issue":"3","key":"10.1016\/j.thromres.2018.01.006_bb0100","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2141.2011.08753.x","article-title":"Guidelines on oral anticoagulation with warfarin - fourth edition","volume":"154","author":"Keeling","year":"2011","journal-title":"Br. J. Haematol."},{"issue":"3","key":"10.1016\/j.thromres.2018.01.006_bb0105","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1016\/j.thromres.2010.06.017","article-title":"French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding)","volume":"126","author":"Pernod","year":"2010","journal-title":"Thromb. Res."},{"issue":"6","key":"10.1016\/j.thromres.2018.01.006_bb0110","first-page":"1113","article-title":"Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants","volume":"114","author":"Weitz","year":"2015","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.01.006_bb0115","series-title":"Prothrombin Complex Concentrate Reverses the Effects of High-dose Rivaroxaban in Rats","volume":"37","author":"Perzborn","year":"2010"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2018.01.006_bb0120","first-page":"148","article-title":"Reversibility of the anticoagulation effects of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VIIa or activated prothrombin complex concentrate","volume":"93","author":"van Ryn","year":"2008","journal-title":"Haematologica"},{"issue":"14","key":"10.1016\/j.thromres.2018.01.006_bb0125","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/CIRCULATIONAHA.111.029017","article-title":"Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects","volume":"124","author":"Eerenberg","year":"2011","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.thromres.2018.01.006_bb0130","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.114.013445","article-title":"Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate","volume":"131","author":"Zahir","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.thromres.2018.01.006_bb0135","doi-asserted-by":"crossref","DOI":"10.1186\/s12959-017-0129-1","article-title":"The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor","volume":"15","author":"Schultz","year":"2017","journal-title":"Thromb. J."},{"issue":"25","key":"10.1016\/j.thromres.2018.01.006_bb0140","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1056\/NEJMe1513258","article-title":"Antidote for factor Xa anticoagulants","volume":"373","author":"Connors","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11S","key":"10.1016\/j.thromres.2018.01.006_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajem.2016.09.045","article-title":"Introduction to direct oral anticoagulants and rationale for specific reversal agents","volume":"34","author":"Pollack","year":"2016","journal-title":"Am. J. Emerg. Med."},{"issue":"3","key":"10.1016\/j.thromres.2018.01.006_bb0150","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCULATIONAHA.116.021831","article-title":"Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents","volume":"134","author":"Ruff","year":"2016","journal-title":"Circulation"},{"issue":"18","key":"10.1016\/j.thromres.2018.01.006_bb0155","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.thromres.2018.01.006_bb0160","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.thromres.2018.01.006_bb0165","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thromb. Haemost."},{"issue":"9994","key":"10.1016\/j.thromres.2018.01.006_bb0170","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(15)60732-2","article-title":"Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial","volume":"386","author":"Glund","year":"2015","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.thromres.2018.01.006_bb0175","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2217\/fca-2016-0070","article-title":"Clinical implications of reversal agents for direct oral anticoagulants","volume":"13","author":"Monagle","year":"2017","journal-title":"Futur. Cardiol."},{"issue":"4","key":"10.1016\/j.thromres.2018.01.006_bb0180","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm.3102","article-title":"A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa","volume":"19","author":"Lu","year":"2013","journal-title":"Nat. Med."},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2018.01.006_bb0185","article-title":"A phase 2 randomized, double-blind, placebocontrolled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors","volume":"11","author":"Crowther","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2018.01.006_bb0190","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1182\/blood.V124.21.4269.4269","article-title":"A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (fXa) inhibitors","volume":"124","author":"Crowther","year":"2014","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.thromres.2018.01.006_bb0195","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","article-title":"Andexanet alfa for the reversal of factor Xa inhibitor activity","volume":"373","author":"Siegal","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.thromres.2018.01.006_bb0200","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"Connolly","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.thromres.2018.01.006_bb0205","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.thromres.2016.07.008","article-title":"Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin","volume":"146","author":"Ansell","year":"2016","journal-title":"Thromb. Res."},{"issue":"22","key":"10.1016\/j.thromres.2018.01.006_bb0210","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMc1411800","article-title":"Use of PER977 to reverse the anticoagulant effect of edoxaban","volume":"371","author":"Ansell","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2018.01.006_bb0215","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/jth.13227","article-title":"Subcommittee on control of anticoagulation, when and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH","volume":"14","author":"Levy","year":"2016","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.thromres.2018.01.006_bb0220","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.chest.2017.02.009","article-title":"Direct oral anticoagulant- or warfarin-related major bleeding characteristics, reversal strategies, and outcomes from a multicenter observational study","volume":"152","author":"Xu","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.thromres.2018.01.006_bb0225","series-title":"Management of Major Bleeding and Outcomes in Patients Treated With DOACs: Results From the START SCC Event Register","author":"Testa","year":"2017"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300069?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384818300069?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T01:36:32Z","timestamp":1571276192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384818300069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":45,"alternative-id":["S0049384818300069"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.006","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidotes for the direct oral anticoagulants: What news?","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2018.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}